<SEC-DOCUMENT>0001140361-22-027565.txt : 20220801
<SEC-HEADER>0001140361-22-027565.hdr.sgml : 20220801
<ACCEPTANCE-DATETIME>20220801083200
ACCESSION NUMBER:		0001140361-22-027565
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220731
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220801
DATE AS OF CHANGE:		20220801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		221122914

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>edge20002003x10_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:cbio="http://ir.catalystbiosciences.com/20220731" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Soultions, Inc.
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_173f54fb239a48f6bea4a020a9dc0853" contextRef="c20220731to20220731" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_73535ce92bbe4669b005f2f5d07c4e81" contextRef="c20220731to20220731">0001124105</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="cbio-20220731.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20220731to20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-31</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
<div>UNITED STATES</div>
</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_b0fd0b6431794f3995b3b92e5701aaa1" contextRef="c20220731to20220731">8-K</ix:nonNumeric></div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_2f0d024087a04791bbd81102218d28cc" contextRef="c20220731to20220731" format="ixt:datemonthdayyearen">July 31, 2022</ix:nonNumeric></div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_f520a2f74e584f5ca15d3fd0354ed531" contextRef="c20220731to20220731">CATALYST BIOSCIENCES, INC.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    <div> <br />
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_419b59746a06439684d76f1ac0f735a9" contextRef="c20220731to20220731" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_a9c8fc16e5af474981c7378a5141e7dc" contextRef="c20220731to20220731">000-51173</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 32.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_e50edb5a93cc4aceb2bcecec733e57a8" contextRef="c20220731to20220731">56-2020050</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(State or other jurisdiction</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Commission</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">File Number)</div>
          </td>

    <td style="width: 32.66%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(IRS Employer</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Identification No.)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_3350e007e8294fba9df286ef0a6a2421" contextRef="c20220731to20220731">611 Gateway Blvd, Suite 710</ix:nonNumeric>,
      <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_beaceac06a8f48e1830291ee897741c5" contextRef="c20220731to20220731">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_88a4a0a8ae7d4bdb960e13c8cf171e8b" contextRef="c20220731to20220731">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_bfdafd412ff14fc789da9e63db3fbda8" contextRef="c20220731to20220731">94080</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Address of principal executive offices)</div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_76e3c5b99b2241f0abd66893cc811701" contextRef="c20220731to20220731">650</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_f9993aeba5f44ae8a87c8ba45cc0fe73" contextRef="c20220731to20220731">871-0761</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Not Applicable</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Former name or former address, if changed since last
        report.)</span></div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.7%; vertical-align: top;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_d13febc3da3b4144966d2ba1ffbcf80e" contextRef="c20220731to20220731" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: 96.3%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.91%; vertical-align: top;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_acd32b32afb5409d8021b217542d343a" contextRef="c20220731to20220731" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: 96.09%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.7%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_172d2f7f39584ab0b64604ea1677ff11" contextRef="c20220731to20220731" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 96.3%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </span><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.7%; vertical-align: top;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_dba8a0359ebb4f9285725c215bef2920" contextRef="c20220731to20220731" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
          </td>

    <td style="width: 96.3%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b)
              of the Act:</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 28.92%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 27.49%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Trading Symbol(s)</div>
          </td>

    <td style="width: 43.59%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 28.92%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_c31b376346c0454e86a687605832cc6b" contextRef="c20220731to20220731">Common Stock</ix:nonNumeric><br />
          </td>

    <td style="width: 27.49%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_01e2497d9de445219fe8d175ed1077d5" contextRef="c20220731to20220731">CBIO</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 43.59%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_aa9cbe32a3054c56b452ccae86301258" contextRef="c20220731to20220731" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric><br />
            </div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter)
      or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_1d0c006a21ab48278bca9426b3d40420" contextRef="c20220731to20220731" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
<div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9744;</span></div>

      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div><br />
    </div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 8.01</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Other



        Events.</span></div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On July 31, 2022, Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) entered into an Agreement (the &#8220;Agreement&#8221;), with JEC II Associates, LLC, The Heidi S.
      Shippell-Heiland 2008 Irrevocable Trust and Michael Torok (collectively, the &#8220;Investors&#8221;). As of the date of the Agreement, the Investors collectively beneficially owned an aggregate of 2,505,000 shares, or approximately 8.0%, of outstanding common
      stock. Under the Agreement, each of the Investors agreed to vote all of the Company&#8217;s shares beneficially owned by such Investor in favor of the Company&#8217;s nominees for the Board of Directors (the &#8220;Board&#8221;) at the Company&#8217;s upcoming 2022 Annual Meeting
      of Stockholders.</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Investors shall have the right to appoint one individual as non-voting observer to the Board to attend all meetings of the Transaction Committee of the
      Board and any portion of Board meetings and meetings of any other Board committee in which there is discussion of a material corporate transaction, dividend or other distribution to Company stockholders, or matters related to the pending litigation
      filed by JDS1, LLC and its affiliates and the proxy solicitation initiated by JDS1, LLC and its affiliates to elect three individuals to the Board. In addition, the Investors agreed to certain customary standstill, nondisclosure and confidentiality
      provisions.</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A copy of the Agreement is included as Exhibit 99.1. The foregoing description of the Agreement is not purported to be complete and qualified in its entirety
      by reference to the full text of the Agreement, which is incorporated herein by reference.</div>

    <div><br />
    </div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 9.01</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Financial



        Statements and Exhibits.</span></div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)&#160; Exhibits</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6.57%; vertical-align: middle; border-bottom: 2px solid black;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit No.</div>
          </td>

    <td style="width: 3.36%; vertical-align: middle;">&#160;</td>

    <td style="width: 83.78%; vertical-align: middle; border-bottom: 2px solid black;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
          </td>

    <td style="width: 6.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6.57%; vertical-align: middle;">&#160;</td>

    <td style="width: 3.36%; vertical-align: middle;">&#160;</td>

    <td style="width: 83.78%; vertical-align: middle;">&#160;</td>

    <td style="width: 6.3%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6.57%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="edge20002003x10_ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 3.36%; vertical-align: top;">&#160;</td>

    <td colspan="2" style="width: 90.07%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Agreement, effective as of July 31, 2022, between Catalyst Biosciences, Inc. and certain Investors specified therein.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 6.57%; vertical-align: top;">&#160;</td>

    <td style="width: 3.36%; vertical-align: top;">&#160;</td>

    <td colspan="2" style="width: 90.07%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 6.57%; vertical-align: top;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="edge20002003x10_ex99-2.htm">99.2</a></div>
          </td>

    <td style="width: 3.36%; vertical-align: top;">&#160;</td>

    <td colspan="2" style="width: 90.07%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Press Release dated August 1, 2022.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
      <div style="page-break-after:always;" class="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

    </div>

    <div><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div><br />
    </div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
      hereunto duly authorized.</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50.45%; vertical-align: top;">&#160;</td>

    <td style="width: 49.55%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CATALYST BIOSCIENCES, INC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50.45%; vertical-align: middle;">&#160;</td>

    <td style="width: 49.55%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50.45%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Date: August 1, 2022</div>
          </td>

    <td style="width: 49.55%; vertical-align: bottom; border-bottom: 2px solid #000000;">
            <div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Nassim Usman</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 50.45%; vertical-align: top;">&#160;</td>

    <td style="width: 49.55%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nassim Usman, Ph.D.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50.45%; vertical-align: top;">&#160;</td>

    <td style="width: 49.55%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">President and Chief Executive Officer</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>edge20002003x10_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; margin-left: 381.6pt; color: #000000; font-weight: bold;">Exhibit 99.1</div>
      <div><br>
      </div>
      <div style="text-align: right; margin-left: 381.6pt; color: #000000; font-weight: bold;">Execution Version</div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Confidential</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Agreement</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This agreement<font style="font-weight: bold;">&#160;</font>(the &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;) is made and entered into as of July 31, 2022
        (the &#8220;<font style="font-weight: bold; font-style: italic;">Effective Date</font>&#8221;) by and among Catalyst Biosciences, Inc., a Delaware corporation (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), and each of the parties
        listed on <font style="font-weight: bold;"><u>Exhibit A</u></font> hereto (each, an &#8220;<font style="font-weight: bold; font-style: italic;">Investor</font>&#8221; and collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Investors</font>&#8221;
        or, with their respective Affiliates and Representatives, the &#8220;<font style="font-weight: bold; font-style: italic;">Investor Group</font>&#8221;). The Company and each of the Investors are each herein referred to as a &#8220;<font style="font-weight: bold; font-style: italic;">party</font>&#8221; and collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">parties</font>.&#8221;)</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><font style="font-weight: bold;">Whereas</font>, each of the Investors beneficially owns the number of shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<font style="font-weight: bold; font-style: italic;">Common Stock</font>&#8221;), listed on <u>Exhibit A</u> hereto;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><font style="font-weight: bold;">Whereas</font>, the Company has reached an agreement with each of the Investors with respect to certain matters as provided in this Agreement;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><font style="font-weight: bold;">Whereas</font>, the 2022 annual meeting of stockholders of the Company (the &#8220;<font style="font-weight: bold; font-style: italic;">2022</font>&#160;<font style="font-weight: bold; font-style: italic;">Annual Meeting</font>&#8221;) is scheduled to be held on August 15, 2022;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><font style="font-weight: bold;">Whereas</font>, on June 15, 2022, JDS1, LLC and its Affiliates filed a lawsuit captioned JDS1, LLC v. Catalyst Biosciences, Inc., C.A. No.
        2022-0350-KSJM (Del. Ch.) against the Company pursuant to Section 220 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) and another lawsuit captioned JDS1, LLC v. Catalyst Biosciences, Inc., et al., C.A. No. 2022-0515-KSJM (Del. Ch.) against the
        Company and the Company&#8217;s Board of Directors (the &#8220;<font style="font-weight: bold; font-style: italic;">Board</font>&#8221;) alleging, among other things, violations of Section 271 of the DGCL (the &#8220;<font style="font-weight: bold; font-style: italic;">JDS1



          Litigations</font>&#8221;);</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><font style="font-weight: bold;">Whereas</font>, JDS1, LLC and its Affiliates initiated a proxy solicitation to elect three individuals to the Company&#8217;s Board (the &#8220;<font style="font-weight: bold; font-style: italic;">JDS1 Proxy</font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><font style="font-weight: bold;">Now, Therefore</font>, in consideration of the premises and mutual covenants and agreements set forth herein, and for other good and valuable
        consideration, the receipt and sufficiency of which are hereby acknowledged, the Investors, on a several and not joint basis, and the Company hereby agree as follows:</div>
      <div><br>
      </div>
      <div style="margin-left: 36pt;"><font style="font-weight: bold; color: #000000;">Section 1.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Voting Agreement</u></font><u>.</u></font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Each of the Investors agrees to vote, or provide a written consent or proxy with respect to, all shares of Common Stock beneficially owned by such Investor in favor of the election
        of any director nominee nominated by the Company&#8217;s Board at the 2022 Annual Meeting; <font style="font-style: italic;">provided, however</font>, that no such vote, consent or proxy shall be required if the Board makes any declaration or takes any
        action that is materially inconsistent with or contrary to the statements in the press release described in <u>Section 6</u> (a &#8220;<font style="font-weight: bold; font-style: italic;">Contrary Event</font>&#8221;).</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <br>
      <div>
        <div>
          <div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 2.</font>
              <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Appointment of the Board Observer</u></font>.</font></div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(i)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">The Investor Group shall have the right to appoint one individual as non-voting observer to the Board (the &#8220;</font><font style="font-weight: bold; font-style: italic; color: #000000;">Board Observer</font><font style="color: #000000;">&#8221;), which appointment shall first become effective upon written notice to the Company. The Board Observer shall be entitled to attend all meetings
          (including telephonic and or videoconference meetings) of the Transaction Committee (the &#8220;</font><font style="font-weight: bold; font-style: italic; color: #000000;">Committee</font><font style="color: #000000;">&#8221;) and any portion of Board
          meetings and meetings of any other Board committee in which a material corporate transaction, dividend or other distribution to Company stockholders, or matters related to the JDS1 Litigations and the JDS1 Proxy are discussed, in a non-voting
          observer capacity and, in this respect, shall receive copies of the applicable portion of all notices, minutes, consents, and other materials and information&#160; (the &#8220;</font><font style="font-weight: bold; font-style: italic; color: #000000;">Relevant

          Materials and Information</font><font style="color: #000000;">&#8221;) that the Company provides to the directors of the applicable committee and the Board at the same time and in the same manner as provided to such directors; </font><font style="font-style: italic;">provided</font><font style="font-style: italic; color: #000000;">&#160;</font><font style="color: #000000;">that the Board Observer may from time to time revocably elect, upon written notice, to receive the Relevant
          Materials and Information only with respect to certain committees or meetings, including limited to the Transaction Committee of the Board. The Company reserves the right to withhold any information and to exclude the Board Observer from any
          meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or a conflict of interest, or
          if such Investor Group or any of its Representatives is a competitor of the Company. Under no circumstances shall the Board Observer be counted for purposes of voting, quorum or any other reason or be considered a director. </font>&#160;<font style="color: #000000;">The Board Observer appointed by the Investor Group may be replaced or removed (with or without cause) from time to time and at any time by the Investor Group upon written notice to the Company, provided that any
          replacement Board Observer shall be acceptable to the Board.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(ii)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">The Board Observer shall be entitled to advancement of expenses and rights to indemnification from the Company to the same extent provided by
          the Company to its directors under the Certificate of Incorporation and Bylaws of the Company (and the related indemnification agreements) as in effect on the date hereof, provided that no indemnification or advancement of expenses shall be
          available for claims related to a breach of this Agreement by the Board Observer, any Investor or their respective Associates, Affiliates, or Representatives, or for any claims brought against the Company by the Board Observer, any Investor or
          their respective Associates, Affiliates, or Representatives. The Company acknowledges and agrees that the foregoing rights to indemnification and advancement of expenses constitute third-party rights extended to the Board Observer by the Company,
          shall not terminate (notwithstanding any termination of this Agreement or the other covenants set forth in this <u>Section 2</u>), and do not constitute rights to indemnification or advancement of expenses as a result of the Board Observer
          serving as a director, officer, employee, or agent of the Company.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(iii)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;">The covenants set forth in this <u>Section 2</u> shall terminate and be of no further force or effect immediately on the earliest of (a) the date on which the Board has
        declared one or more dividends on shares of the Company&#8217;s Common Stock or otherwise distributed cash to holders of the Company&#8217;s Common Stock with a value of $65,000,000 in the aggregate, (b) a change in control of the Company, (c) eighteen (18)
        months from the Effective Date, (d) the date at which the Investor Group no longer owns any shares of Common Stock or (e) the date at which the Investor Group provides written notice to the Company of its voluntary termination of its right to
        appoint a Board Observer.</div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"> <br>
      </div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"> <br>
      </div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="margin-left: 36pt;"><font style="font-weight: bold; color: #000000;">Section 3.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Nondisclosure Agreement</u></font><u>.</u></font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(i)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">The Investor Group, the Board Observer, and any and all of their Associates, Affiliates, and Representatives (collectively the &#8220;</font><font style="font-weight: bold; font-style: italic; color: #000000;">Receiving Party</font><font style="color: #000000;">&#8221;) agree to hold in confidence all the Confidential Information (defined below) and agree to not disclose such Confidential
          Information (other than disclosures to the Investor Group, its Associates, its Affiliates, or to any of its or their Representatives) without the Company or the Board&#8217;s prior written approval. The Receiving Party shall hold and maintain the
          Confidential Information in strictest confidence; </font><font style="font-style: italic; color: #000000;">provided, however</font><font style="color: #000000;">, that the foregoing shall not apply to the extent the Investor Group, its
          Associates, Affiliates, and Representatives, or the Board Observer is compelled to disclose the Confidential Information by judicial or administrative process pursuant to the advice of counsel or by requirements of law, provided that the
          Receiving Party shall provide the Company (a) prompt notice to any such compelled or required disclosure to enable to the Company to seek a protective order or similar remedy, and (b) reasonable cooperation with respect to any effort by the
          Company to seek a protective order or similar remedy. Upon written request of the Company or the Board, the Receiving Party shall promptly return or destroy, at the Receiving Party&#8217;s option, any and all records, notes, and other written, printed,
          or tangible materials in its possession pertaining to the Confidential Information; </font><font style="font-style: italic; color: #000000;">provided, however</font><font style="color: #000000;">, that each of the Investor Group, its Affiliates,
          and its and their Representatives may retain any electronic or written copies of Confidential Information as may be stored on its electronic records or storage system resulting from automated back-up systems or required by law, other regulatory
          requirements, or internal document retention policies</font>. The Investor Group shall be liable for any unauthorized disclosure of Confidential Information by its or the Board Observer&#8217;s respective Associates, Affiliates and Representatives.
        Notwithstanding <u>Section 17</u>, each Receiving Party&#8217;s obligations under this <u>Section 3</u> shall survive termination or expiration of this Agreement until twelve (12) months after the date the Receiving Party received the last of such
        Confidential Information.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(ii)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">As used in this Agreement, &#8220;<font style="font-weight: bold; font-style: italic;">Confidential Information</font>&#8221; means any and all information
          or data concerning the Company, whether in verbal, visual, written, electronic, or other form, which is disclosed to the Board Observer in his or her role as Board Observer by the Company or any director, officer, employee, or agent of the
          Company (including all Relevant Materials and Information that is non-public information); <font style="font-style: italic;">provided, however</font>, that &#8220;Confidential Information&#8221; shall not include information that:</font></div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc722d22a631046a2baf1872cf5c708f1">

          <tr>
            <td style="width: 90pt;"><br>
            </td>
            <td style="width: 54pt; vertical-align: top; align: right; color: #000000;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">is or becomes generally available to the public other than as a result of disclosure of such information by the Investor Group, the Board Observer, and any and all of their Associates, Affiliates, and
                Representatives;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdb54630a21574a2294dbc705b2c69025">

          <tr>
            <td style="width: 90pt;"><br>
            </td>
            <td style="width: 54pt; vertical-align: top; align: right; color: #000000;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">is independently developed by the Investor Group, any of its Affiliates, any of their Representatives, or the Board Observer without use of Confidential Information provided by the Company or by any director,
                officer, employee, or agent thereof;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z036d741291274d85a417580b44963833">

          <tr>
            <td style="width: 90pt;"><br>
            </td>
            <td style="width: 54pt; vertical-align: top; align: right; color: #000000;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">becomes available to the recipient of such information at any time on a non-confidential basis from a third party that is not, to the recipient&#8217;s knowledge, prohibited from disclosing such information to the
                Investor Group or any of its Affiliates, any of their respective Representatives, or the Board Observer by any contractual, legal, or fiduciary obligation to the Company; or</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb3b0352e479644c68f6a0e9c363df352">

          <tr>
            <td style="width: 90pt;"><br>
            </td>
            <td style="width: 54pt; vertical-align: top; align: right; color: #000000;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">was known by the Investor Group, any of its Affiliates, or the Board Observer prior to receipt from the Company or from any director, officer, employee, or agent thereof.</div>
            </td>
          </tr>

      </table>
      <br>
      <div>
        <div>
          <div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 4.</font>
              <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Acknowledgment of Obligations under Securities Laws</u></font>.</font></div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The Investor Group and any Affiliate, Associate or Representative thereof, including the Board Observer, acknowledge and agree that each is aware of the restrictions imposed by the
        federal securities laws and other applicable foreign and domestic laws (the &#8220;<font style="font-weight: bold; font-style: italic;">Securities Laws</font>&#8221;) on a person possessing material nonpublic information about a publicly traded company. Each
        of the Investor Group and any Affiliate, Associate or Representative thereof, including the Board Observer, hereby agrees that, while it is in possession of such material nonpublic information, it will not violate such Securities Laws.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <br>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 5.</font>
            <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Standstill</u></font>.</font></div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Each Investor agrees that, for the period commencing on the date of this Agreement and ending on the earliest of (i) the one year anniversary of the Agreement, (ii) a material
        breach by the Company of its obligations under this Agreement which is not cured within five (5) Business Days after written notice from any Investor, (iii) the date of any Contrary Event or (iv) the termination of the board observation covenants
        set forth in <u>Section 2</u> (the &#8220;<font style="font-weight: bold; font-style: italic;">Standstill Period</font>&#8221;), neither it nor any of its controlled Affiliates will, and it will cause each of its controlled Affiliates not to, directly or
        indirectly, acting alone or in concert with others:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(i)</font>
        <div style="margin: -16px 0px 0px; text-indent: 108pt;"><font style="color: #000000;">submit any stockholder proposal (pursuant to Rule 14a-8 promulgated by the SEC under the Exchange Act or otherwise) or any notice of nomination or other business
            for consideration, or nominate any candidate for election to the Board (including by way of Rule 14a-11 of Regulation 14A), other than as expressly permitted by this Agreement;</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(ii)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">engage in, directly or indirectly, any &#8220;solicitation&#8221; (as defined in Rule 14a-1 of Regulation 14A) of proxies (or written consents) or
          otherwise become a &#8220;participant in a solicitation&#8221; (as such term is defined in Instruction 3 of Schedule 14A of Regulation 14A under the Exchange Act) in opposition to the recommendation or proposal of the Board, or recommend or request or induce
          or attempt to induce any other person to take any such actions, or seek to advise, encourage or influence any other person with respect to the voting of the Common Stock (including any withholding from voting) or grant a proxy with respect to the
          voting of the Common Stock or other voting securities to any person other than to the Board or persons appointed as proxies by the Board;</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(iii)</font>
        <div style="margin: -16px 0px 0px; text-indent: 108pt;"><font style="color: #000000;">seek to call, or to request the call of, a special meeting of the Company&#8217;s stockholders, or make a request for a list of the Company&#8217;s stockholders or to inspect
            any books and records of the Company;</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(iv)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">form, join in or in any other way participate in a &#8220;partnership, limited partnership, syndicate or other group&#8221; within the meaning of Section
          13(d)(3) of the Exchange Act with respect to the Common Stock or deposit any shares of Common Stock in a voting trust or similar arrangement or subject any shares of Common Stock to any voting agreement or pooling arrangement, other than a group
          consisting only of some or all of the Investors and their Affiliates;</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(v)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">seek to place a Representative or other Affiliate or nominee on the Board or seek the removal of any member of the Board or a change in the
          size or composition of the Board;</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(vi)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">acquire or agree, offer, seek or propose to acquire, or cause to be acquired, ownership (including beneficial ownership) of any of the assets
          or business of the Company or any rights or options to acquire any such assets or business from any person, in each case other than securities of the Company;</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(vii)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">other than at the direction of the Board, seek, propose or make any statement (other than to one or more members of the Board or management or
          its advisors or agents) with respect to, or solicit, or negotiate with or provide any information to any person with respect to, a merger, consolidation, acquisition of control or other business combination, tender or exchange offer, purchase,
          sale or transfer of assets or securities, dissolution, liquidation, reorganization, change in structure or composition of the Board, change in the executive officers of the Company, change in capital structure, recapitalization, dividend, share
          repurchase or similar transaction involving the Company, its subsidiaries or its business, whether or not any such transaction involves a change of control of the Company (it being understood that the foregoing shall not restrict the Investors
          from tendering Common Stock, receiving payment for Common Stock or otherwise participating in any such transaction on the same basis as other stockholders of the Company, or from participating in any such transaction that has been approved by the
          Board);</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(viii)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">acquire, announce an intention to acquire, offer or propose to acquire, or agree to acquire, directly or indirectly, by purchase or otherwise,
          beneficial ownership of (A) any interests in the Company&#8217;s indebtedness or (B) an aggregate amount of more than 9.99% of the Company&#8217;s outstanding Common Stock (which shall not include Common Stock issued in connection with a stock split, stock
          dividend or similar corporate action initiated by the Company with respect to any securities beneficially owned by any of the Investors or their Affiliates); <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>,
          nothing herein shall prevent any Investor from confidentially seeking a waiver from this provision;</font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(ix)</font>
        <div style="margin: -16px 0px 0px; text-indent: 108pt;"><font style="color: #000000;">short sell the Company&#8217;s capital stock, or otherwise pledge, hypothecate or put any liens against the Company&#8217;s capital stock, except that an Investor may partake
            in customary margin transactions with a broker regulated by FINRA;</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(x)</font>
        <div style="margin: -16px 0px 0px; text-indent: 108pt;"><font style="color: #000000;">disclose publicly, or privately in a manner that could reasonably be expected to become public, any intention, plan or arrangement inconsistent with the
            foregoing;</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(xi)</font>
        <div style="margin: -16px 0px 0px; text-indent: 108pt;"><font style="color: #000000;">take any action challenging the validity or enforceability of any provisions of this <u>Section 5</u>; or</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="color: #000000;">(xii)</font></div>
      <div style="margin: -16px 0px 0px; text-align: justify; text-indent: 108pt;"><font style="color: #000000;">enter into any agreement, arrangement or understanding concerning any of the foregoing (other than this Agreement) or encourage or solicit any
          person to undertake any of the foregoing activities.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Except as expressly provided in <u>Section 2</u>, the Investor Group shall be entitled to (i) vote any shares of Common Stock that it beneficially owns as it determines in its sole
        discretion and (ii) disclose, publicly or otherwise, how it intends to vote or act with respect to any securities of the Company, any stockholder proposal or other matter to be voted on by the stockholders of the Company and the reasons therefor.</div>
      <br>
      <div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 6.</font>
          <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Public Announcement</u></font>.</font></div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Following the execution of this Agreement, the Company shall issue a press release substantially in the form attached hereto as <font style="font-weight: bold;"><u>Exhibit B</u></font>.</div>
      <div><br>
        <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 7.</font>
          <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Representations and Warranties of the Company</u></font>.</font></div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The Company represents and warrants to the Investor Group that (a) the Company has the corporate power and authority to execute this Agreement and to bind it thereto, (b) this
        Agreement has been duly and validly authorized, executed and delivered by the Company, and assuming due execution by each counterparty hereto, constitutes a valid and binding obligation and agreement of the Company, and is enforceable against the
        Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to
        general equity principles, and (c) to the actual knowledge of the executive officers of the Company, the execution, delivery and performance of this Agreement by the Company does not and will not (i) violate or conflict with any law, rule,
        regulation, order, judgment or decree applicable to the Company, or (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both would constitute such a breach, violation or default)
        under or pursuant to, or result in the loss of a material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document or material agreement to which the Company is a party or by which it
        is bound.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 8.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Representations and Warranties of the Investors</u></font>.</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">The Investor Group represents and warrants to the Company that (a) the authorized signatory of each Investor set forth on the signature pages hereto has the power and authority to
        execute this Agreement and any other documents or agreements to be entered into in connection with this Agreement and to bind such Investor thereto, (b) this Agreement has been duly authorized, executed and delivered by each Investor, and assuming
        due execution by each counterparty hereto, is a valid and binding obligation of such Investor, enforceable against such Investor in accordance with its terms except as enforcement thereof may be limited by applicable bankruptcy, insolvency,
        reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, (c) the execution of this Agreement, the consummation of any of the transactions contemplated
        hereby, and the fulfillment of the terms hereof, in each case in accordance with the terms hereof, will not conflict with, or result in a breach or violation of the organizational documents of each Investor as currently in effect and (d) to the
        actual knowledge of each Investor, the execution, delivery and performance of this Agreement by such Investor does not and will not (i) violate or conflict with any law, rule, regulation, order, judgment or decree applicable to such Investor, or
        (ii) result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both would constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit under,
        or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such Investor is a party or by which it is bound.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <br>
      <div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 9.</font>
          <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Definitions</u></font>.</font></div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">As used in this Agreement:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaaee4244f45549da949103e1ce4a6869">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">a.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the term &#8220;<font style="font-weight: bold; font-style: italic;">Affiliate</font>&#8221; shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z850271a6c6164c2d945ac21a3e418df0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the term &#8220;<font style="font-weight: bold; font-style: italic;">Associate</font>&#8221; shall have the meaning set forth in Rule 12b-2 promulgated by the SEC under the Exchange Act;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z611d89661ff54af39e24ef09ff3cd2c7">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">c.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the terms &#8220;<font style="font-weight: bold; font-style: italic;">beneficial owner</font>&#8221; and &#8220;<font style="font-weight: bold; font-style: italic;">beneficial ownership</font>&#8221; shall have the same meanings as set
                forth in Rule 13d-3 promulgated by the SEC under the Exchange Act;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbda51df4e88c4f6da86fe8024ee43ea4">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">d.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the<font style="color: #000000;">&#160;</font>term &#8220;<font style="font-weight: bold; font-style: italic;">Business Day</font>&#8221; means any day that is not a Saturday, Sunday or other day on which commercial banks in the State of California are
                authorized<font style="color: #000000;">&#160;</font>or obligated to be closed by applicable law<font style="color: #000000;">;</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcccc568d4a744b52b4bf3cbd515a9491">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">e.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the term &#8220;<font style="font-weight: bold; font-style: italic;">change of control</font>&#8221; shall mean the sale of all or substantially all the assets of the Company; any merger, consolidation or acquisition of the
                Company with, by or into another corporation, entity or person; or any change in the ownership of more than 50% of the voting capital stock of the Company in one or more related transactions;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0b2a67bd555a4b4aa3b4b1193079b741">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">f.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the terms &#8220;<font style="font-weight: bold; font-style: italic;">group</font>,&#8221; &#8220;<font style="font-weight: bold; font-style: italic;">proxy</font>&#8221; and &#8220;<font style="font-weight: bold; font-style: italic;">solicitation</font>&#8221; (and any<font style="color: #000000;">&#160;</font>plurals thereof) have the meanings ascribed to such terms under the Exchange Act and the rules and regulations promulgated thereunder, provided,<font style="color: #000000;">&#160;</font>that the meaning of
                &#8220;solicitation&#8221; shall be without regard to the exclusions set forth in Rules 14a-1(l)(2)(iv) and 14a-2 under the Exchange Act;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za53f16330cb34399a1eeaf5790f132a7">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">g.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: #000000;">the terms &#8220;<font style="font-weight: bold; font-style: italic;">person</font>&#8221; or &#8220;<font style="font-weight: bold; font-style: italic;">persons</font>&#8221; shall mean any individual, corporation (including
                not-for-profit), general or limited partnership, limited liability company, joint venture, estate, trust, association, organization or other entity of any kind or nature;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z542e7e04fb1f4d9aaadf36fcffc8b047">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-weight: bold;">h.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the term &#8220;<font style="font-weight: bold; font-style: italic;">Representatives</font>&#8221; means (i) a person&#8217;s Affiliates and Associates and (ii) its and their respective directors, officers,<font style="color: #000000;">&#160;</font>employees,
                partners, members, managers, consultants, legal or other advisors, agents and other representatives acting in a capacity on behalf of, in<font style="color: #000000;">&#160;</font>concert with or at the direction of such person or its Affiliates
                or Associates;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zce0185125df041e3afe48dc42506c7a9">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-weight: bold;">i.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the term &#8220;<font style="font-weight: bold; font-style: italic;">third party</font>&#8221; refers to any person that is not a party, a member of the Board, a director or officer of the Company, or legal counsel to either party.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8b2e298b0e144a4eb4acbda320978cb6">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; font-weight: bold;">j.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In this Agreement, unless a clear contrary intention appears, (i) the word &#8220;including&#8221; (in its various forms) means &#8220;including, without limitation;&#8221; (ii) the words &#8220;hereunder,&#8221; &#8220;hereof,&#8221; &#8220;hereto&#8221; and words of similar import are
                references in this Agreement as a whole and not to any particular provision of this Agreement; (iii) the word &#8220;or&#8221; is not exclusive; (iv) references to &#8220;Sections&#8221; in this Agreement are references to Sections of this Agreement unless
                otherwise indicated; and (v) whenever the context requires, the masculine gender shall include the feminine and neuter genders <font style="color: #000000;">hereto will not take action, directly or indirectly, in opposition to the Moving
                  Party seeking such relief on the grounds that any other remedy or relief is available.</font></div>
            </td>
          </tr>

      </table>
      <br>
      <div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 10.</font>
          <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 90px;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Notice</u></font>.</font></div>
        </div>
        <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to
        have been delivered: (i) upon receipt, when delivered personally; or (ii) one (1) Business Day after deposit with a nationally recognized overnight delivery service and concurrently sent by e-mail, in each case properly addressed to the party to
        receive the same. The addresses and e-mail addresses for such communications shall be:</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div style="color: #000000;"><u>To the Company:</u></div>
      <div><br>
      </div>
      <div style="margin-left: 72pt; color: #000000;">Catalyst Biosciences, Inc.</div>
      <div style="margin-left: 72pt; color: #000000;">Attention: Nassim Usman, Ph.D.</div>
      <div style="margin-left: 72pt; color: #000000;">611 Gateway Blvd., Suite 710</div>
      <div style="margin-left: 72pt; color: #000000;">South San Francisco, CA 94080</div>
      <div style="margin-left: 72pt; color: #000000;">Telephone: (650) 871-0761</div>
      <div style="margin-left: 72pt; color: #0000FF;"><u>E-mail: nusman@catbio.com</u></div>
      <div><br>
      </div>
      <div style="margin-left: 72pt; color: #000000;">with a copy to (which shall not constitute notice):</div>
      <div><br>
      </div>
      <div style="margin-left: 72pt; color: #000000;">Orrick, Herrington &amp; Sutcliffe LLP</div>
      <div style="margin-left: 72pt; color: #000000;">Attention: Stephen Thau</div>
      <div style="margin-left: 72pt; color: #000000;">51 W 52<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> St</div>
      <div style="margin-left: 72pt; color: #000000;">New York, NY 10019</div>
      <div style="margin-left: 72pt; color: #000000;">Telephone: (212) 506-5076</div>
      <div style="margin-left: 72pt; color: #0000FF;"><u>E-mail: sthau@orrick.com</u></div>
      <div><br>
      </div>
      <div style="color: #000000;"><u>To the Investors</u>: As set forth in the respective addresses listed in <u>Exhibit A</u> hereto with a copy to (which shall not constitute notice):</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; margin-left: 36pt; color: #000000;">Baker Botts L.L.P.</div>
      <div style="text-indent: 36pt; margin-left: 36pt; color: #000000;">Attention: Travis J. Wofford</div>
      <div style="text-indent: 36pt; margin-left: 36pt; color: #000000;">910 Louisiana Street</div>
      <div style="text-indent: 36pt; margin-left: 36pt; color: #000000;">Houston, Texas 77002</div>
      <div style="text-indent: 36pt; margin-left: 36pt; color: #000000;">Telephone: (713) 229-1234</div>
      <div style="text-indent: 36pt; margin-left: 36pt; color: #000000;">E-mail: travis.wofford@bakerbotts.com</div>
      <div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 11.</font>
          <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Governing Law</u></font>.</font></div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Agreement shall be governed by, and construed in accordance with, the law of the State of Delaware, without regard to conflict of law principles thereof, and each party
        irrevocably submits to the personal jurisdiction of the Chancery Court of Delaware as the exclusive venue for adjudication of any dispute hereunder.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 12.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Entire Agreement</u></font>.</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Agreement constitutes the full and entire understanding and agreement among the parties with regard to the subject matter hereof, and supersedes all prior agreements with
        respect to the subject matter hereof. The Company may enter into a materially similar agreement with one or more other investors but any such agreement shall constitute a separate obligation and one investor shall not become a third party
        beneficiary of another investor&#8217;s agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 13.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Receipt of Adequate Information; No Reliance; Representation by Counsel</u></font><u>.</u></font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Each party acknowledges that it has received adequate information to enter into this Agreement, that it has not relied on any promise, representation or warranty, express or implied
        not contained in this Agreement and that it has been represented by counsel in connection with this Agreement. Accordingly, any rule of law or any legal decision that would provide any party with a defense to the enforcement of the terms of this
        Agreement against such party shall have no application and is expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to effect the intent of the parties.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <br>
      <div>
        <div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 14.</font>
            <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Expenses</u></font>.</font></div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">Within five (5) Business Days of the Effective Date, the Company shall reimburse the Investor Group for its out-of-pocket fees and expenses (including legal expenses) incurred in
        connection with the Investor Group&#8217;s involvement at the Company through the date of this Agreement, including, but not limited to its Schedule 13D filings, its engagement with members of the Company&#8217;s management team and stockholders, and the
        execution of this Agreement, provided that such reimbursement shall not exceed $25,000 in the aggregate.</div>
      <div><br>
      </div>
      <div>
        <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 15.</font>
          <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Severability</u></font>.</font></div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">If any provision of this Agreement is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement shall remain in full force<font style="font-weight: bold;">&#160;</font>and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or unenforceable. The parties further agree
        to replace such invalid or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the purposes of such invalid or unenforceable provision.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 16.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Amendment</u></font>.</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Agreement may be modified, amended or otherwise changed only in a writing signed by all of the parties.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 17.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Termination</u></font>.</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Agreement shall terminate at the end of the Standstill Period or other date established by mutual written agreement of the parties hereto. Notwithstanding the foregoing, the
        provisions of <u>Section 9</u> thru <u>Section 19</u><font style="font-weight: bold;">&#160;</font>and <u>Section 2(ii)</u> shall survive the termination of this Agreement. No termination of this Agreement shall relieve any Party from liability for
        any breach of this Agreement prior to such termination.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 18.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Successors and Assigns; No Third Party Beneficiaries</u></font>.</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Agreement shall bind the successors and permitted assigns of the Parties, and inure to the benefit of any successor or permitted assign of any of the parties; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that no party may assign this Agreement without the prior written consent of the other parties. Except as set forth in <u>Section 2</u>, no provision
        of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any person other than the parties hereto and their respective successors and assigns.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: #000000;">Section 19.</font>
        <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 72pt;"><font style="color: #000000;"><font style="font-weight: bold;"><u>Counterparts</u></font>.</font></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;">This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same
        instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. Counterparts delivered by electronic transmission shall be deemed to be originally signed
        counterparts.</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000;">(<font style="font-style: italic;">Signature page follows</font>)</div>
      <div style="text-align: center; color: #000000;"> <br>
      </div>
      <div style="text-align: center; color: #000000;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <br>
      <div style="text-align: justify; text-indent: 36pt; color: #000000;"><font style="font-weight: bold;">In Witness Whereof</font>, the parties hereto have duly executed and delivered this Agreement as of the date first above written.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zfff2111061784ee1a4a7e56e33e3f76d">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Catalyst Biosciences, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Name:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">/s/ Nassim Usman, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Name:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Nassim Usman, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Title:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">President and Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z1994ae0dd38f47dfa11055e89d50fb1f">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">JEC II Associates, LLC</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Name:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">/s/ Michael Torok</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Name:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Michael Torok</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Title:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Manager</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zde91bd50d77f414b800eacfc02219cd1">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Heidi S. Shippell-Heiland 2008 Irrevocable Trust</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">/s/ Michael Torok</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Name:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Michael Torok</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Title:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Trustee</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: top;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Michael Torok</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">/s/ Michael Torok</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <br>
      <div style="text-align: center; color: #000000; font-weight: bold;"><u>Exhibit A</u></div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8298eb0debfd4b5dbba57b676c534639">

          <tr>
            <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000; font-weight: bold;"><u>Investor</u></div>
            </td>
            <td style="width: 33.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000; font-weight: bold;"><u>Shares of Common Stock Beneficially Owned</u></div>
              <div>&#160;</div>
            </td>
            <td style="width: 34%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; color: #000000; font-weight: bold;"><u>Notice</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">JEC II Associates, LLC</div>
            </td>
            <td style="width: 33.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">1,550,000</div>
            </td>
            <td style="width: 34%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); color: rgb(0, 0, 0);">
              <div style="text-align: center; margin-left: 10.8pt; font-family: 'Times New Roman',Times,serif;">910 Louisiana Street</div>
              <div style="text-align: center; margin-left: 10.8pt; font-family: 'Times New Roman',Times,serif;">Houston, Texas 77002</div>
              <div style="text-align: center; margin-left: 10.8pt; font-family: 'Times New Roman',Times,serif;">Tel: (713) 229-1234</div>
              <div style="text-align: center; margin-left: 10.8pt; font-family: 'Times New Roman',Times,serif;"><u>E-mail: travis.wofford@bakerbotts.com</u></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">The Heidi S. Shippell-Heiland 2008 Irrevocable Trust</div>
            </td>
            <td style="width: 33.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">250,000</div>
            </td>
            <td style="width: 34%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); color: rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">910 Louisiana Street</div>
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Houston, Texas 77002</div>
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">Tel: (713) 229-1234</div>
              <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><u>E-mail: travis.wofford@bakerbotts.com</u></div>
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">Michael Torok</div>
            </td>
            <td style="width: 33.34%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000;">2,505,000</div>
            </td>
            <td style="width: 34%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); color: rgb(0, 0, 0);">
              <div style="text-align: center; margin-left: 10.8pt; font-family: 'Times New Roman',Times,serif;">910 Louisiana Street</div>
              <div style="text-align: center; margin-left: 10.8pt; font-family: 'Times New Roman',Times,serif;">Houston, Texas 77002</div>
              <div style="text-align: center; margin-left: 10.8pt; font-family: 'Times New Roman',Times,serif;">Tel: (713) 229-1234</div>
              <div style="text-align: center; margin-left: 10.8pt; font-family: 'Times New Roman',Times,serif;"><u>E-mail: travis.wofford@bakerbotts.com</u></div>
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>edge20002003x10_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 22.7.2.5062
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">Exhibit 99.2<br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">FINAL &#8211; FOR RELEASE AUGUST 1, 2022 at 7:30AM EST</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Catalyst Biosciences Announces Support from Largest Single Stockholder</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">JEC Capital Partners Agrees to Vote Its Shares in Favor of Catalyst&#8217;s Nominees at the Company&#8217;s 2022 Annual Meeting</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Michael Torok from JEC Appointed as an Observer to the Transaction Committee of the Board of Directors</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Company Has Committed to Announcing a Record Date for a Substantial Distribution of Cash to Stockholders as Soon as Litigation and Proxy
      Fight are Resolved</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Catalyst Calls Upon JDS1 to Drop Its Litigation and Proxy Contest so the Company Can Expeditiously Execute Its Cash Distribution Plan</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SOUTH SAN FRANCISCO, Calif., August 1, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (&#8220;Catalyst,&#8221; the &#8220;Company&#8221; or &#8220;we&#8221;) today announced
      that it has reached an agreement with its largest single stockholder<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup>, JEC II Associates, LLC (&#8220;JEC&#8221;), under which JEC has committed to vote all of the Catalyst shares over which it has voting authority in favor of Catalyst&#8217;s nominees for
      the Board of Directors on the Company&#8217;s <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>WHITE</u></font> proxy card at the Company&#8217;s upcoming 2022 Annual Meeting of Stockholders (the &#8220;Annual
      Meeting&#8221;), scheduled to be held on August 15, 2022. In addition, Michael Torok, the Managing Director of JEC, has been appointed as an observer to the Transaction Committee of the Company&#8217;s Board of Directors, effective immediately.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Separately, the Board has committed to distributing a significant portion of the Company&#8217;s available cash to stockholders (the &#8220;Cash Distribution Plan&#8221;) and
      announcing a record date for that distribution within five business days following the conclusion of the Company&#8217;s Delaware litigation and proxy contest with JDS1, LLC (&#8220;JDS1&#8221;), assuming that no other litigation arises beforehand. If the litigation
      and proxy contest are concluded soon and without much additional expense, the Company expects that initial distribution to be $45 million. As the Company stated in a letter to stockholders on July 19, 2022, we estimate that we may ultimately provide
      stockholders up to $65 million in cash, in one or more distributions, and we continue to pursue the monetization of our remaining assets that may generate additional value.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;We are pleased to have the support of our largest stockholder during a pivotal time in our Company&#8217;s history, as we seek to expeditiously distribute the
      Company&#8217;s available cash and monetize the Company&#8217;s remaining assets,&#8221; said Augustine Lawlor, Chairman of Catalyst. &#8220;We have appreciated JEC&#8217;s input into our strategic plan, and we value Mr. Torok&#8217;s insights and his constructive approach to the
      discussions. The Board welcomes Mr. Torok&#8217;s participation in future meetings of the Transaction Committee and looks forward to his contributions.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;I applaud the Catalyst Board of Directors for its actions in exploring strategic alternatives and for developing the Cash Distribution Plan,&#8221; said Michael
      Torok, Managing Director of JEC. &#8220;I am fully supportive of this Plan, and I call upon JDS1 to drop its proxy contest and litigation so that the Company can make its initial distribution of cash to shareholders. I am pleased to support the Company&#8217;s
      nominees at the Annual Meeting and I look forward to my role as an observer to the Transaction Committee as it works to monetize additional assets and implement the Cash Distribution Plan.&#8221;</div>
    <br>
    <br>
    <hr noshade="noshade" align="left" style="text-align: left; background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> Source: FactSet</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Catalyst urges other stockholders to join JEC in supporting the Cash Distribution Plan by voting <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#8220;FOR&#8221; ALL</font> nominees on the <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><u>WHITE</u></font> proxy card.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Catalyst Biosciences</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Catalyst is a biotechnology company focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems.
      After the transaction of its complement pipeline, Catalyst&#8217;s product candidates consist of the coagulation related assets marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), dalcinonacog alfa (&#8220;DalcA&#8221;), and CB 2679d-GT. MarzAA is a SQ administered next
      generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. DalcA is a next-generation SQ administered FIX. CB 2679d-GT is an AAV-based gene therapy
      construct harboring the DalcA sequence. Both MarzAA and DalcA have shown sustained efficacy and safety in mid-stage clinical trials and are available for partnering. CB 2679d-GT has obtained preclinical proof-of-concept and is also available for
      partnering.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Additional Information and Where to Find It</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) has filed a definitive proxy statement, an accompanying WHITE proxy card and other relevant documents with the
      Securities and Exchange Commission (the &#8220;SEC&#8221;) in connection with the solicitation of proxies for the Company&#8217;s 2022 annual meeting of stockholders (the &#8220;Annual Meeting&#8221;). BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF THE COMPANY ARE URGED TO
      READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY&#8217;S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to
      obtain a copy of the definitive proxy statement and other documents filed by the Company with the SEC free of charge from the SEC&#8217;s website at www.sec.gov. In addition, copies will be available at no charge by selecting &#8220;Financials &amp; Filings&#8221; in
      the &#8220;Investors&#8221; tab of the Company&#8217;s website at www.catalystbiosciences.com.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Certain Information Regarding Participants in the Solicitation</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company, its directors and certain of its executive officers will be participants in the solicitation of proxies from the Company&#8217;s stockholders in
      connection with the Annual Meeting. The names of these directors and executive officers and their respective direct and indirect interests, by security holdings or otherwise, in the Company are set forth in the Company&#8217;s definitive proxy statement
      filed with the SEC on July 19, 2022.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include, without
      limitation, those regarding the amount and timing of planned cash distributions, potential uses of and markets for MarzAA, DalcAA and CB 2679-GT, and Catalyst&#8217;s plans to continue to explore strategic alternatives. Actual results or events could
      differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risks
      that Catalyst&#8217;s obligations and liabilities will be greater than currently anticipated, that the pending litigation and anticipated proxy contest with JDS1 will not be resolved in a timely manner and the expenses associated with that litigation will
      be greater than anticipated, that Catalyst will not be able to identify strategic partners interested in MarzAA, DalcAA, CB 2679-GT or any other transaction with the Company, and other risks described in the &#8220;Risk Factors&#8221; section of the Company&#8217;s
      Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 31, 2022, the Quarterly Report on Form 10-Q filed with the SEC on May 9, 2022, and in other filings filed from time to time with the SEC. The Company
      does not assume any obligation to update any forward-looking statements, except as required by law.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contact Information</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trisha Colton</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Catalyst Biosciences, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">investors@catbio.com</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cbio-20220731.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.7.2.5062 Broadridge-->
<xs:schema targetNamespace="http://ir.catalystbiosciences.com/20220731" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:cbio="http://ir.catalystbiosciences.com/20220731" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="cbio-20220731_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cbio-20220731_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cbio-20220731_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.7.2.5062 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cbio-20220731_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 22.7.2.5062 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="cbio-20220731.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139706825278896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CATALYST BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Blvd, Suite 710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-0761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBIO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>edge20002003x10_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cbio-20220731.xsd" xlink:type="simple"/>
    <context id="c20220731to20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20220731to20220731"
      id="Fact_173f54fb239a48f6bea4a020a9dc0853">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20220731to20220731"
      id="Fact_73535ce92bbe4669b005f2f5d07c4e81">0001124105</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20220731to20220731"
      id="Fact_b0fd0b6431794f3995b3b92e5701aaa1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20220731to20220731"
      id="Fact_2f0d024087a04791bbd81102218d28cc">2022-07-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20220731to20220731"
      id="Fact_f520a2f74e584f5ca15d3fd0354ed531">CATALYST BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20220731to20220731"
      id="Fact_419b59746a06439684d76f1ac0f735a9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20220731to20220731"
      id="Fact_a9c8fc16e5af474981c7378a5141e7dc">000-51173</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20220731to20220731"
      id="Fact_e50edb5a93cc4aceb2bcecec733e57a8">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20220731to20220731"
      id="Fact_3350e007e8294fba9df286ef0a6a2421">611 Gateway Blvd, Suite 710</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20220731to20220731"
      id="Fact_beaceac06a8f48e1830291ee897741c5">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20220731to20220731"
      id="Fact_88a4a0a8ae7d4bdb960e13c8cf171e8b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20220731to20220731"
      id="Fact_bfdafd412ff14fc789da9e63db3fbda8">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20220731to20220731"
      id="Fact_76e3c5b99b2241f0abd66893cc811701">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20220731to20220731"
      id="Fact_f9993aeba5f44ae8a87c8ba45cc0fe73">871-0761</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20220731to20220731"
      id="Fact_d13febc3da3b4144966d2ba1ffbcf80e">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20220731to20220731"
      id="Fact_acd32b32afb5409d8021b217542d343a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20220731to20220731"
      id="Fact_172d2f7f39584ab0b64604ea1677ff11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20220731to20220731"
      id="Fact_dba8a0359ebb4f9285725c215bef2920">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20220731to20220731"
      id="Fact_c31b376346c0454e86a687605832cc6b">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20220731to20220731"
      id="Fact_01e2497d9de445219fe8d175ed1077d5">CBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20220731to20220731"
      id="Fact_aa9cbe32a3054c56b452ccae86301258">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20220731to20220731"
      id="Fact_1d0c006a21ab48278bca9426b3d40420">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MH(>OC+I44-SG'V4$,9EO9(;5BA:109]>>OT>Q8CJ8D'/JA;3E*NUR-;D RA
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
M8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSA
MR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB
M0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>
M@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&
M8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%
M=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM(+#5
M2?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS8]$7
M>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;
MIJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=Y
MYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNH
MR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \
M& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH
M=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z
M@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^
M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ _$,!59E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #\0P%5N]$#HU,$  "3$   &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ _$,!59^@&_"Q @  X@P   T
M             ( !E@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #\0P%5
MEXJ[',     3 @  "P              @ %R#P  7W)E;',O+G)E;'-02P$"
M% ,4    " #\0P%5'#AEZC\!   \ @  #P              @ %;$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ _$,!520>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ _$,!5660>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="edge20002003x10_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="edge20002003x10_8k.htm">edge20002003x10_8k.htm</File>
    <File>cbio-20220731.xsd</File>
    <File>cbio-20220731_lab.xml</File>
    <File>cbio-20220731_pre.xml</File>
    <File>edge20002003x10_ex99-1.htm</File>
    <File>edge20002003x10_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "edge20002003x10_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "edge20002003x10_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cbio-20220731_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbio-20220731_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cbio-20220731.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "cbio",
   "nsuri": "http://ir.catalystbiosciences.com/20220731",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edge20002003x10_8k.htm",
      "contextRef": "c20220731to20220731",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "edge20002003x10_8k.htm",
      "contextRef": "c20220731to20220731",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-22-027565-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-027565-xbrl.zip
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MFH^V8Q*W$#/S'<ZD/S+IC^*359R%PGR^CQ1@O4W8,S]ZY\=1OZKO/$"/C.H
M)O#YT2'W/6,'?%TLS=!C5[V1M#ZD?+PN*&10<;&YT_/CCT"3Y79+<LJ):+[?
M>]7(^9?U,:__7J79^]]P:O2AV_/2'\9>,7]#VKG<"K&/HY+LZ@]02P,$%
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M,36\^ND-SXM,YA5>+<"E4MNL/$*L,JG5!/3P^3A2!TU"GH+[A28#'K);],.
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M5Q \TURGZA@YF0XQ 5A*[I^0MB=O#[_M1+SV3L0+.MB#_L_G)]=?KA;7#>]
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M#MB0X87!KH!X68;'R-]]D_21I@B(4+[*"@E(MI %<*0<$6R9I2N0&I YP<O
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M$5#Y$DL\:I@=:BD)*%B4<H*M2GQ*2'.2)MJ>+2[X&CA?K,461QRMBM'":_@
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MG9B'7%S'K=QE:A)Q:L,:8 ;NFU +OVP*&C4J3512#"P>V#2NPNZN3W7S?N/
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M-K'BK-#5GM[ ,@!5DTB*1FX5_ZO,XM<X%%P+6[!-E*O0#3OJ]N187FP?M3N
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M&51ZR1(W[KXMD<Q2K8D?4Z#\PC%B3EVC:&/7&3X7KF^:RKB))0N8"HS,6C?
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M+3(P,C(P-S,Q+GAS9%!+ 0(4 Q0    ( /Q# 558LES*?P@  '18   5
M          "  7T#  !C8FEO+3(P,C(P-S,Q7VQA8BYX;6Q02P$"% ,4
M" #\0P%5DFE;4N8%   -/P  %0              @ $O#   8V)I;RTR,#(R
M,#<S,5]P<F4N>&UL4$L! A0#%     @ _$,!59OA7@8!$P  %&T  !8
M         ( !2!(  &5D9V4R,# P,C P,W@Q,%\X:RYH=&U02P$"% ,4
M" #\0P%5PL9*5FTQ  !I-0$ &@              @ %])0  961G93(P,# R
M,# S>#$P7V5X.3DM,2YH=&U02P$"% ,4    " #\0P%5P$6\\G8/   I-0
M&@              @ $B5P  961G93(P,# R,# S>#$P7V5X.3DM,BYH=&U0
52P4&      8 !@"9 0  T&8

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
